EU regulator starts a review of Russia's COVID-19 vaccine

Thursday, March 4, 2021 | Maria Cheng And Daria Litvinova, Associated Press

Russia's Sputnik V coronavirus vaccine arrives at Kosice Airport, Slovakia, on Monday March 1, 2021. In a statement Thursday March 4, 2021, the European Medicines Agency regulator says it has started a rolling review of the Sputnik V vaccine that appears to be safe and effective, months after the vaccine was first approved for use in Russia and after dozens of countries around the world have authorized it. (Frantisek Ivan/TASR via AP)

MOSCOW (AP) — The European Medicines Agency has started a rolling review of Russia's Sputnik V coronavirus vaccine, many months after it was first approved for use in Russia and after dozens of countries around the world have authorized it.

In a statement Thursday, the European regulator said the review is based on results from lab studies and research in adults, which suggests the vaccine may help protect against the coronavirus.

Despite skepticism about Russia’s hasty introduction of the vaccine, which was rolled out before it had completed late-stage trials, the vaccine appears to be safe and effective. According to a study published last month in the journal Lancet, Sputnik V is 91% effective and appears to prevent inoculated individuals from becoming severely ill with COVID-19, although it's still unclear if the vaccine can prevent the spread of the disease.

With a global shortage of COVID-19 vaccines, some experts say boosting the use of vaccines made by China and Russia — which have not been as in demand as those made by Western companies — could offer a quicker way to increase the global supply. The pandemic has already infected over 115 million people, killing over 2.5 million of them, according to a tally by Johns Hopkins University.

The EMA has so far approved three COVID-19 vaccines for use across the 27-nation European Union: shots made by Pfizer-BioNtech, Moderna and AstraZeneca. It could license a fourth shot made by Johnson & Johnson at an expert meeting next Thursday.

The EMA has not set a date for when its expert group might meet to assess Sputnik V data but the rolling review aims to expedite the authorization process, which can typically take months.

Dr. Hans Kluge, the World Health Organization’s regional director for Europe, called the EMA announcement on Sputnik V “good news.”

“We desperately need to enlarge our portfolio of vaccines, so I see this as a very welcome development,” Kluge said.

In the meantime, dozens of countries have already authorized Sputnik V for use — including EU member Hungary — and many have agreed to purchase millions of doses of the shot.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund that bankrolled the development of the vaccine, said Thursday that “vaccine partnerships should be above politics and cooperation with EMA is a perfect example, demonstrating that pooling efforts is the only way to end the pandemic.”

“Following EMA approval, we would be able to provide vaccines for 50 million Europeans starting from June,” Dmitriev added.

The European Commission, the EU’s executive arm, said Thursday it is not looking to add the Russian vaccine to its portfolio at this stage.

“No talks are ongoing between negotiation teams and the producers, or institutes, or companies or organizations behind the Sputnik vaccine,” said Stefan De Keersmaecker, the Commission’s health policy spokesman.

The RDIF has been pushing for the EMA to review Sputnik V for months, with Dmitriev first announcing an application to the European regulator in November. In January, the EMA met with the developers of the vaccine.

Although there was considerable scientific skepticism when Russia unrolled its vaccine without completing advanced trials, many doubts have since been assuaged with the publication of it latest research. Experts said Russia’s initial immunization campaign was marred by “unseemly haste, corner cutting and an absence of transparency.”

Sputnik V uses a modified version of the common cold-causing adenovirus to carry genes for the spike protein into the coronavirus to prime the body to react if COVID-19 comes along. That’s a similar technology to the vaccine developed by AstraZeneca and Oxford University.

But unlike AstraZeneca’s two-dose vaccine, Sputnik V uses a slightly different adenovirus for the second booster shot, a factor that some scientists say may account for its apparently high efficacy rate.

The World Health Organization is also considering whether or not to issue an emergency use approval for Sputnik V; officials last month were awaiting further details from its Russian developers. That approval would be essential for any Sputnik V vaccines to be used in the U.N.-backed COVAX program to try to distribute vaccines fairly to nations around the world, but COVAX has not yet signed any deals for Sputnik V.

Questions have been raised in the West over Russia's eagerness to export its vaccine amid its comparatively slow domestic vaccine rollout — officials say nearly 4 million people, less than 3% of Russia's population of 146 million, have received the shots so far.

“I must say we still wonder why Russia is offering theoretically millions and millions of doses while not sufficiently progressing in vaccinating their own people,” European Commission President Ursula von der Leyen said.

Kremlin spokesman Dmitry Peskov retorted that Russia’s vaccination campaign is going at “normal” rates, adding that the international demand for Sputnik V is “so high that it significantly exceeds (Russia's) production capacity.”

The RDIF says it has received requests for 2.4 billion doses of the two-shot vaccine, enough to immunize 1.2 billion people, from over 50 countries. According to Prime Minister Mikhail Mishustin, Russia has so far produced just over 10 million doses.


Jamey Keaten in Geneva and Samuel Petrequin in Brussels contributed to this report.

Follow AP’s pandemic coverage at, and

Featured Article: Futures Contract

7 Stocks It May Be Time To Take Profits On

Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.

Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.

Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.

View the "7 Stocks It May Be Time To Take Profits On".

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)2.7$162.24+1.2%2.49%25.51Buy$182.62
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.